ストックスクリーナーアプリを入手
7.97
6.89%
-0.59
アフターアワーズ：
8.08
0.11
+1.38%
Candel Therapeutics Inc (CADL) 最新ニュース
This Small-Cap Biotech Is Having Its Best Week In A Month – Here’s What’s Driving It - Stocktwits
Candel Therapeutics eyes year-end BLA after strong prostate cancer data - MSN
trust me - Moomoo
Avoiding Lag: Real-Time Signals in (CADL) Movement - Stock Traders Daily
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish - TradingView
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Candel Therapeutics, Inc. posts new long term trial results for aglatimagene besadenovec - Traders Union
Candel Therapeutics stock falls despite phase 3 trial publication - Investing.com
CADL Achieves Significant Milestone in Prostate Cancer Treatment - GuruFocus
Candel publishes phase 3 prostate cancer trial results - Investing.com UK
Candel Therapeutics stock falls despite phase 3 trial publication By Investing.com - Investing.com South Africa
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer - The Manila Times
Candel publishes phase 3 prostate cancer trial results By Investing.com - Investing.com Australia
Candel Therapeutics Announces Publication in The Lancet - GlobeNewswire
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bank of America Securities Remains a Hold on Candel Therapeutics (CADL) - The Globe and Mail
New hires at Candel Therapeutics get 63,000 stock options - Stock Titan
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Discipline and Rules-Based Execution in CADL Response - Stock Traders Daily
Candel Therapeutics reported better-than-feared Q1 loss – but all eyes turn to this pivotal event tomorrow - MSN
Candel Therapeutics (CADL) Edges Higher, Holds Above Key Support LevelHigh Dividend Factor - thelegaladvocate.com
Loss-Making Candel Therapeutics, Inc. (NASDAQ:CADL) Expected To Breakeven In The Medium-Term - simplywall.st
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade - MSN
Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data - TradingView
Candel Therapeutics, Inc. reveals strategy for advancing prostate cancer and glioma programs - Traders Union
Behavioral Patterns of CADL and Institutional Flows - Stock Traders Daily
Candel Therapeutics reports positive phase 3 prostate cancer trial data - MSN
BofA Securities Maintains Candel Therapeutics(CADL.US) With Hold Rating, Raises Target Price to $9 - Moomoo
BofA raises Candel Therapeutics stock price target on prostate cancer data - Investing.com UK
BofA raises Candel Therapeutics stock price target on prostate cancer data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data - Dailyhunt
Candel Therapeutics Highlights Phase 3 Prostate Cancer Data - The Globe and Mail
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):